Please assess the completion status of the following clinical trial:

Trial Title: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically-confirmed adenocarcinoma of the colon or rectum in patients with unresectable metastatic (M1) disease~* Patients with at least 1 uni-dimensionally measurable lesion of at least 10 mm per modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines~* Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method~* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1~* Men or women 18 years of age or older~* Adequate hematologic, renal, hepatic, metabolic, and coagulation function~Exclusion Criteria:~* History of prior or concurrent central nervous system (CNS) metastases~* Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma~* Clinically significant cardiac disease~* Clinically significant peripheral sensory neuropathy~* Active inflammatory bowel disease~* Recent gastroduodenal ulcer to be active or uncontrolled~* History of interstitial lung disease~* Recent pulmonary embolism, deep vein thrombosis, or other significant venous event~* Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy~* Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab Plus mFOLFOX6 (Type: EXPERIMENTAL): Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU) (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
- Bevacizumab Plus mFOLFOX6 (Type: ACTIVE_COMPARATOR): Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).